Biora Therapeutics (BIOR)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.20 mm | 3.20 mm | 3.20 mm | 3.20 mm | 3.20 mm | 3.20 mm |
Cash burn (monthly) | 709.67 k | 781.08 k | 7.42 mm | 5.77 mm | 2.91 mm | 3.83 mm |
Cash used (since last report) | 3.59 mm | 3.96 mm | 37.58 mm | 29.24 mm | 14.74 mm | 19.38 mm |
Cash remaining | -398.23 k | -759.93 k | -34.39 mm | -26.05 mm | -11.54 mm | -16.19 mm |
Runway (months of cash) | -0.6 | -1.0 | -4.6 | -4.5 | -4.0 | -4.2 |
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 6 |
Closed positions | 13 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 6.19 bn |
Total shares | 80.67 mm |
Total puts | 300.00 |
Total calls | 103.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Athyrium Opportunities III Co-Invest 1 | 25.44 mm | $16.93 mm |
Highbridge Capital Management | 19.96 mm | $69.46 mm |
Athyrium Opportunities 2020 | 19.31 mm | $0.00 |
Athyrium Capital Management | 10.93 mm | $5.48 bn |
CVI Investments | 3.75 mm | $0.00 |
Vanguard | 697.33 k | $350.06 mm |
Geode Capital Management | 156.30 k | $78.41 mm |
MS Morgan Stanley | 145.03 k | $72.75 mm |
NTRS Northern Trust | 68.57 k | $34.40 mm |
BlackRock | 61.61 k | $30.90 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Aug 24 | Aditya P. Mohanty | Common Stock | Payment of exercise | Dispose F | No | No | 0.67 | 70,883 | 47.49 k | 1,468,609 |
15 Aug 24 | dEsparbes Eric | Common Stock | Payment of exercise | Dispose F | No | No | 0.67 | 27,830 | 18.65 k | 575,832 |
15 Aug 24 | Clarke Neumann | Common Stock | Payment of exercise | Dispose F | No | No | 0.67 | 26,629 | 17.84 k | 465,564 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 0.6 | 457,250 | 274.35 k | 457,250 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Sale back to company | Dispose D | Yes | No | 0.63 | 457,250 | 288.07 k | 0 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 0.6 | 5,039,236 | 3.02 mm | 5,039,236 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Sale back to company | Dispose D | Yes | No | 5.5 | 5,039,236 | 27.72 mm | 0 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 0.6 | 2,085,372 | 1.25 mm | 2,085,372 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Sale back to company | Dispose D | Yes | No | 5 | 2,085,372 | 10.43 mm | 0 |
12 Aug 24 | Athyrium Opportunities III Co-Invest 1 | Warrant Common Stock | Grant | Acquire A | Yes | No | 0.6 | 500,249 | 300.15 k | 500,249 |